Association between TLR2, MTR, MTRR, XPC, TP73, TP53 genetic polymorphisms and gastric cancer: A meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 3, 2014, Pages 346-359

  Cheng, Chen ^a   Lingyan, Wang ^b   Yi, Huang ^a   Cheng, Zhang ^a   Huadan, Ye ^a   Xuting, Xu ^a   Leiting, Xu ^a   Meng, Ye ^a   Shiwei, Duan ^a  

^a NINGBO UNIVERSITY   (China)

^b NINGBO NO 2 HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; TOLL LIKE RECEPTOR 2; XERODERMA PIGMENTOSUM GROUP C PROTEIN; 5 METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE; DNA BINDING PROTEIN; FERREDOXIN NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE REDUCTASE; MTR PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN P53; TLR2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; XPC PROTEIN, HUMAN;

ARTICLE; CANCER RISK; COMPARATIVE STUDY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; META ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; ANCESTRY GROUP; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; STOMACH TUMOR;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; CONTINENTAL POPULATION GROUPS; DNA-BINDING PROTEINS; FERREDOXIN-NADP REDUCTASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS; TOLL-LIKE RECEPTOR 2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84902540188     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.12.009     Document Type: Article

References (78)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Chen W., Zheng R., Zhang S., Zhao P., Li G., Wu L., et al. The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 2013, 32(3):106-112.
3. Zhang Y., Weck M.N., Schottker B., Rothenbacher D., Brenner H. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev 2013, 22(5):821-826.
4. Lin Y., Ueda J., Kikuchi S., Totsuka Y., Wei W.Q., Qiao Y.L., et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 2011, 17(39):4421-4428.
5. Fukase K., Kato M., Kikuchi S., Inoue K., Uemura N., Okamoto S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008, 372(9636):392-397.
6. Hartgrink H.H., Jansen E.P., van Grieken N.C., van de Velde C.J. Gastric cancer. Lancet 2009, 374(9688):477-490.
7. Wroblewski L.E., Peek R.M., Wilson K.T. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010, 23(4):713-739.
8. Hudler P. Genetic aspects of gastric cancer instability. ScientificWorldJournal 2012, 2012:761909.
9. Persson C., Canedo P., Machado J.C., El-Omar E.M., Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: a huge systematic review and meta-analyses. Am J Epidemiol 2011, 173(3):259-270.
10. Ding S.Z., Torok A.M., Smith M.F., Goldberg J.B. Toll-like receptor 2-mediated gene expression in epithelial cells during Helicobacter pylori infection. Helicobacter 2005, 10(3):193-204.
11. Smith M.F., Mitchell A., Li G., Ding S., Fitzmaurice A.M., Ryan K., et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem 2003, 278(35):32552-32560.
12. Castano-Rodriguez N., Kaakoush N.O., Goh K.L., Fock K.M., Mitchell H.M. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis. PLoS One 2013, 8(4):e60327.
13. Li D., Wang X., Wu J.L., Quan W.Q., Ma L., Yang F., et al. Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro. PLoS One 2013, 8(2):e56616.
14. Kim M.K., Park S.W., Kim S.K., Park H.J., Eun Y.G., Kwon K.H., et al. Association of Toll-like receptor 2 polymorphisms with papillary thyroid cancer and clinicopathologic features in a Korean population. J Korean Med Sci 2012, 27(11):1333-1338.
15. Singh V., Srivastava N., Kapoor R., Mittal R.D. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in a case-control study with bladder cancer susceptibility in a North Indian population. Arch Med Res 2013, 44(1):54-61.
16. Weiner A.S., Gordeeva L.A., Voronina E.N., Boyarskikh U.A., Shabaldin A.V., Filipenko M.L. Polymorphisms in folate-metabolizing genes and risk of having an offspring with congenital anomalies in the West Siberian region of Russia: a case-control study. Prenat Diagn 2012, 32(11):1041-1048.
17. Zhang F.F., Terry M.B., Hou L., Chen J., Lissowska J., Yeager M., et al. Genetic polymorphisms in folate metabolism and the risk of stomach cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(1):115-121.
18. Wu Y., Jin M., Liu B., Liang X., Yu Y., Li Q., et al. The association of XPC polymorphisms and tea drinking with colorectal cancer risk in a Chinese population. Mol Carcinog 2011, 50(3):189-198.
19. Engin A.B., Karahalil B., Engin A., Karakaya A.E. DNA repair enzyme polymorphisms and oxidative stress in a Turkish population with gastric carcinoma. Mol Biol Rep 2011, 38(8):5379-5386.
20. Palli D., Polidoro S., D'Errico M., Saieva C., Guarrera S., Calcagnile A.S., et al. Polymorphic DNA repair and metabolic genes: a multigenic study on gastric cancer. Mutagenesis 2010, 25(6):569-575.
21. Dong Z., Guo W., Zhou R., Wan L., Li Y., Wang N., et al. Polymorphisms of the DNA repair gene XPA and XPC and its correlation with gastric cardiac adenocarcinoma in a high incidence population in North China. J Clin Gastroenterol 2008, 42(8):910-915.
22. Ahmad Aizat A.A., Siti Nurfatimah M.S., Aminudin M.M., Ankathil R. XPC Lys939Gln polymorphism, smoking and risk of sporadic colorectal cancer among Malaysians. World J Gastroenterol 2013, 19(23):3623-3628.
23. Perez-Mayoral J., Pacheco-Torres A.L., Morales L., Acosta-Rodriguez H., Matta J.L., Dutil J. Genetic polymorphisms in RAD23B and XPC modulate DNA repair capacity and breast can-cer risk in Puerto Rican women. Mol Carcinog 2013, 52(Suppl 1):E127-E138.
24. Letkova L., Matakova T., Musak L., Sarlinova M., Krutakova M., Slo-vakova P., et al. DNA repair genes polymorphism and lung cancer risk with the emphasis to sex differences. Mol Biol Rep 2013, 40(9):5261-5273.
25. Jin S., Levine A.J. The p53 functional circuit. J Cell Sci 2001, 114(Pt 23):4139-4140.
26. Zoric A., Horvat A., Slade N. Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis 2013, 34(3):522-529.
27. Zaykin D.V. Optimally weighted Z-test is a powerful method for combining probabilities in meta-analysis. J Evol Biol 2011, 24(8):1836-1841.
28. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
29. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
30. Dupont W.D., Plummer W.D. Power and sample size calculations. A review and computer program. Control Clin Trials 1990, 11(2):116-128.
31. Ott N., Geddert H., Sarbia M. Polymorphisms in methionine synthase (A2756G) and cystathionine beta-synthase (844ins68) and susceptibility to carcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol 2008, 134(3):405-410.
32. Eussen S.J., Vollset S.E., Hustad S., Midttun O., Meyer K., Fredriksen A., et al. Vitamins B2 and B6 and genetic polymorphisms related to one-carbon metabolism as risk factors for gastric adenocarcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2010, 19(1):28-38.
33. Stolzenberg-Solomon R.Z., Qiao Y.L., Abnet C.C., Ratnasinghe D.L., Dawsey S.M., Dong Z.W., et al. Esophageal and gastric cardia cancer risk and folate- and vitamin B(12)-related polymorphisms in Linxian, China. Cancer Epidemiol Biomarkers Prev 2003, 12(11 Pt 1):1222-1226.
34. Ikeda S., Sasazuki S., Natsukawa S., Shaura K., Koizumi Y., Kasuga Y., et al. Screening of 214 single nucleotide polymorphisms in 44 candidate cancer susceptibility genes: a case-control study on gastric and colorectal cancers in the Japanese population. Am J Gastroenterol 2008, 103(6):1476-1487.
35. Hishida A., Matsuo K., Goto Y., Naito M., Wakai K., Tajima K., et al. No associations of Toll-like receptor 2 (TLR2) -196 to -174del polymorphism with the risk of Helicobacter pylori seropositivity, gastric atrophy, and gastric cancer in Japanese. Gastric Cancer 2010, 13(4):251-257.
36. Zeng H.M., Pan K.F., Zhang Y., Zhang L., Ma J.L., Zhou T., et al. Genetic variants of toll-like receptor 2 and 5, helicobacter pylori infection, and risk of gastric cancer and its precursors in a chinese population. Cancer Epidemiol Biomarkers Prev 2011, 20(12):2594-2602.
37. Tahara T., Arisawa T., Wang F., Shibata T., Nakamura M., Sakata M., et al. Toll-like receptor 2-196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci 2007, 98(11):1790-1794.
38. De Feo E., Persiani R., La Greca A., Amore R., Arzani D., Rausei S., et al. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res 2009, 675(1-2):60-65.
39. Ge H., Wang Y.M., Cao Y.Y., Zhang X.F., Li Y., Guo W., et al. Correlation of p73 polymorphisms to genetic susceptibilities to esophageal carcinoma and gastric cardiac carcinoma. Ai Zheng 2006, 25(11):1351-1355.
40. Hamajima N., Matsuo K., Suzuki T., Nakamura T., Matsuura A., Hatooka S., et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002, 181(1):81-85.
41. Shirai O., Ohmiya N., Taguchi A., Nakamura M., Kawashima H., Miyahara R., et al. P53, p21, and p73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology 2010, 57(104):1595-1601.
42. Ye W., Kumar R., Bacova G., Lagergren J., Hemminki K., Nyren O. The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. Carcinogenesis 2006, 27(9):1835-1841.
43. Long X.D., Ma Y., Huang Y.Z., Yi Y., Liang Q.X., Ma A.M., et al. Genetic polymorphisms in DNA repair genes XPC, XPD, and XRCC4, and susceptibility to Helicobacter pylori infection-related gastric antrum adenocarcinoma in Guangxi population, China. Mol Carcinog 2010, 49(6):611-618.
44. Hiyama T., Tanaka S., Kitadai Y., Ito M., Sumii M., Yoshihara M., et al. p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer 2002, 100(3):304-308.
45. Zhang Z.W., Newcomb P., Hollowood A., Feakins R., Moorghen M., Storey A., et al. Age-associated increase of codon 72 arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res 2003, 9(6):2151-2156.
46. Wu M.T., Chen M.C., Wu D.C. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett 2004, 205(1):61-68.
47. Shen H., Solari A., Wang X., Zhang Z., Xu Y., Wang L., et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep 2004, 11(5):1115-1120.
48. Zhou L.Y., Li Gao X.G., et al. Chinese people p53 gene CD72 Arg/Pro polymorphism associated with gastric cardia adenocarcinoma. World J Gastroenterol 2004, 12(8):1955-1957.
49. Alpizar-Alpizar W., Sierra R., Cuenca P., Une C., Mena F., Perez-Perez G.I. Association of the p53 codon 72 polymorphism to gastric cancer risk in a hight risk population of Costa Rica. Rev Biol Trop 2005, 53(3-4):317-324.
50. Mu L.N., Lu Q.Y., Yu S.Z., Jiang Q.W., Cao W., You N.C., et al. Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer 2005, 116(6):972-983.
51. Perez-Perez G.I., Bosques-Padilla F.J., Crosatti M.L., Tijerina-Menchaca R., Garza-Gonzalez E. Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol 2005, 40(1):56-60.
52. Lai K.C., Chen W.C., Jeng L.B., Li S.Y., Chou M.C., Tsai F.J. Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. Eur J Surg Oncol 2005, 31(10):1135-1140.
53. Chung W.C., Lee K.M., Lee B.I., Chun J.S., Lee S.Y., Chang U.I., et al. P53 genetic polymorphism of gastric cancer in Korea. Korean J Intern Med 2006, 21(1):28-32.
54. Belyavskaya V.A., Vardosanidze V.K., Smirnova O.Y., Karakin E.I., Savkin I.V., Gervas P.A., et al. Genetic status of p53 in stomach cancer: somatic mutations and polymorphism of codon 72. Bull Exp Biol Med 2006, 141(2):243-246.
55. Sul J., Yu G.P., Lu Q.Y., Lu M.L., Setiawan V.W., Wang M.R., et al. P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett 2006, 238(2):210-223.
56. Yi S.Y., Lee W.J. A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol 2006, 12(40):6536-6539.
57. Ke-Xiang Z., Yu-Min L., Xun L., Wen-Ce Z., Yong S., Tao L. Study on the association of p53 codon 72 polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu Province in China. Mol Biol Rep 2012, 39(1):723-728.
58. Dora C.R., Juan E.C.C.M., et al. Gastric cancer, tobacco usage, alcohol consumption, socioeconomic stratification and polymorphism in codon 72 of gene p53 in a population of Manizales. Biosalud 2007, 6(1):33-44.
59. Yang M., Guo Y., Zhang X., Miao X., Tan W., Sun T., et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007, 28(9):1996-2001.
60. Cao Y.Y., Ge H., Chen L.Q., Chen Z.F., Wen D.G., Li Y., et al. Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Ai Zheng 2007, 26(10):1052-1057.
61. Capella G., Pera G., Sala N., Agudo A., Rico F., Del Giudicce G., et al. DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol 2008, 37(6):1316-1325.
62. Canas M., Moran Y., Camargo M.E., Rivero M.B., Bohorquez A., Villegas V., et al. TP53 codon 72 polymorphism and gastric cancer risk: a case-control study in individuals from the central-western region of Venezuela. Invest Clin 2009, 50(2):153-161.
63. Gomes de Souza L., Miranda de Lima J., Dale Cotrim Guerreiro da Silva I., Manoukian Forones N. P53 Arg72Pro polymorphism in gastric cancer patients. J Gastrointest Cancer 2009, 40(1-2):41-45.
64. Kim J.M., Lee O.Y., Lee C.G., Kwon S.J., Kim K.S., Moon W., et al. p53 Codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans. Korean J Gastroenterol 2007, 50(5):292-298.
65. Shan Yong M.L., Xun Li, et al. Study of p53 gene codon 72 Arg/Pro polymorphism in high incidence area of gastric cancer in Gansu Province. Chin J Bases Clin General Surg 2009, 16(1):12-17.
66. Kim N., Cho S.I., Lee H.S., Park J.H., Kim J.H., Kim J.S., et al. The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. Dig Dis Sci 2010, 55(1):101-110.
67. Mojtahedi Z., Haghshenas M.R., Hosseini S.V., Fattahi M.J., Ghaderi A. p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer 2010, 47(1):31-34.
68. Hua Z.W., Qin X.G.L.Y., et al. Association of genetic polymorphisms of p73 gene and p53 gene with the risk of gastric cancer in Wuwei Population. China Cancer 2011, 20(11):810-815.
69. Engin A.B., Karahalil B., Karakaya A.E., Engin A. Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and colorectal cancer in Turkish population. Arh Hig Rada Toksikol 2011, 62(3):207-214.
70. Song H.R., Kweon S.S., Kim H.N., Piao J.M., Yun W.J., Choi J.S., et al. p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer 2011, 14(3):242-248.
71. Ihsan R., Devi T.R., Yadav D.S., Mishra A.K., Sharma J., Zomawia E., et al. Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol 2011, 30(3):163-171.
72. Zhou Y., Li N., Zhuang W., Wu X. p53 Codon 72 polymorphism and gastric cancer risk in a Chinese Han population. Genet Test Mol Biomarkers 2010, 14(6):829-833.
73. Ihsan R., Devi T.R., et al. Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol 2011, 30(3):163-171.
74. Chen J.G., Xia J.C., Liang X.T., Pan K., Wang W., Lv L., et al. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int J Biol Sci 2011, 7(1):53-60.
75. Panani A.D. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett 2008, 266(2):99-115.
76. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358(6381):15-16.
77. Bellini M.F., Cadamuro A.C., Succi M., Proenca M.A., Silva A.E. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 2012, 2012:891961.
78. Dahabreh I.J., Schmid C.H., Lau J., Varvarigou V., Murray S., Trikalinos T.A. Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol 2013, 177(12):1317-1325.